Dataset on patients with Recurrent Borderline Ovarian Tumors and Table with Review of Literature on Fertility and Oncologic Outcomes of patients with Borderline Ovarian Tumors
Helmut Plett, MD,
Enzo Ricciardi, MD, PhD,
Philipp Harter, MD, PhD,
Beyhan Ataseven, MD, PhD,
Florian Heitz, MD,
Sonia Prader, MD,
Stephanie Schneider, MD,
Sebastian Heikaus, MD, PhD,
Annette Fisseler-Eckhoff, MD, PhD,
Friedrich Kommoss, MD, PhD,
Sigurd F. Lax, MD, PhD,
Annette Staebler, MD, PhD,
Alexander Traut,
Andreas du Bois, MD, PhD
Affiliations
Helmut Plett, MD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology, Charité University Hospital, Berlin, Germany; Corresponding author: Dr. med. Helmut Plett, Dept. of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany, Phone: +49 20117434044; Facsimile: +49 20117434540.
Enzo Ricciardi, MD, PhD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
Philipp Harter, MD, PhD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
Beyhan Ataseven, MD, PhD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany
Florian Heitz, MD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology, Charité University Hospital, Berlin, Germany
Sonia Prader, MD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
Stephanie Schneider, MD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
Sebastian Heikaus, MD, PhD
Center of Pathology Essen-Mitte, Essen, Germany
Annette Fisseler-Eckhoff, MD, PhD
Institute of Pathology, Helios Dr. Horst-Schmidt-Kliniken, Wiesbaden, Germany
Friedrich Kommoss, MD, PhD
Institute of Pathology, Medizin Campus Bodensee, Friedrichshafen, Germany
Sigurd F. Lax, MD, PhD
Department of Pathology, LKH Graz II, Graz and Johannes Kepler University, Linz, Austria
Annette Staebler, MD, PhD
Institute of Pathology and Neuropathology, University of Tuebingen, Germany
Alexander Traut
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
Andreas du Bois, MD, PhD
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
The data presented here is related to the research article entitled “FERTILITY-SPARING SURGERY AND REPRODUCTIVE-OUTCOMES IN PATIENTS WITH BORDERLINE OVARIAN TUMORS” by Plett et al. in Journal of Gynecologic Oncology [1] and is analysed and discussed in detail. 18 Patients with Recurrent Borderline Ovarian Tumors (BOT) were identified and listed in Table 1. All patients underwent treatment for primary BOT either per radical surgery (RS) or fertility sparing surgery (FSS) by the same team in Horst Schmidt Klinik (HSK) in Wiesbaden and the Department of Gynecology and Gynecologic Oncology at Kliniken Essen-Mitte between January 2000 and December 2018 and were followed up closely. Details on patients` and surgical characteristics are given as well as management of character of recurrent disease. In Table 2 important publications from the last 20 years are listed in order to visualize better the oncologic outcomes (invasive and non-invasive relapses) and calculated risks of recurrence with the purpose to understand better the important findings of the related article cited above.
